| [Objectives] (1) To determine the levels of CRP and IL-6 in plasma from patients with CAD, and investigate the relationship between these levels and the degree of severity of CAD. (2) To investigate the relationship between IL-6, CRP and prognosis of these patients with CAD. (3) Also to discuss the possible mechanisms by which they participate in CAD and to observe the effect of other CAD risk factors on plasma IL-6, CRP.[Methods] CRP and IL-6 levels in plasma were assayed by ELISA and Radioimmunoassay from 163 patients with CAD. These patients included 76 patients with AMI, 53 ones with UAP, 34 ones with SAP. The study had 39 non-CAD controls. CRPi, IL-61 assayed on the day of onset and CRP2, IL-62 assayed on the day of leaving hospital represented the levels of beginning and recovering of CAD patients respectively. At the same time, WBC, TC, TG, CTN-I were also measured and some clinic data were asked on the day of being hospitalized. These patients with CAD were observed during hospital and within half a year after leaving hospital. In hospital, those CAD patients who suffered from major heart events were assigned to group A, and the other CAD patients who had no such events were assigned to group B. Except for some patients died in hospital, those who sufferedfrom critical cardiovascular events within 6 months after leaving hospital were in group C, and those who had no such events were in group D. Using statistic methods analyze the difference among these groups.[Results] (1) The levels of CRPi and IL-6i in plasma from the CAD group were higher than that of non-CAD controls(19.89 ±14.27mg/L VS 3.52 ± 1. 56mg/L, P=0. 001; 11. 84 ± 6. 37 u g/L VS 7.46± 2. 25 u g/L, P<0.05); (2) CRPi levels in plasma from AMI group or UAP group higher than that of SAP group (32.39 ±20. 46 mg/L VS 3.52 ± 1. 56mg/L, P<0.01; 20.87±4. 29 mg/L VS 3.52±1. 56rag/L, P<0.05) , while there were no significant difference between AMI group and UAP group (32.39±20. 46 mg/L VS 20.87 ± 4.29 mg/L P>0.05) . IL-6i levels in plasma from AMI group were higher than that of UAP group or SAP group ( 16. 28±10. 14u g/L VS 8. 96 ± 2. 79u g/L P<0.01; 16. 28 ± 10. 14 P g/L VS 8.27 ± 3. 06 n g/LP<0.05), however, the levels of IL-6] in plasma were no difference between UAP group and SAP group (8.96 ± 2.79u g/L VS 8.27 ± 3.06n g/L P>0.05).(3) The levels of CRPi and IL-61 in plasma from group A were significantly higher than that of group B, which had statistical significance(37.44±13.26mg/L VS 16.76± 11.43mg/L P<0.05; 25 ± 11.39u g/L VS 13.68 ± 7.48u g/L P<0.05) . (4)The levels of CRPi and IL-6j in plasma were no difference statistically between group C and group D (20.17±11.23mg/L VS 18.67 ± 10.43 mg/L P>0.05; 13.07 ± 5.54 u g/L VS 10.25 ± 2.99 u g/L P>0.05) . The CRPi levels in serum from group C were higher than that of group D (17.47± 10.32mg/L VS 7.63 ± 5.77 mg/L P<0.05) , which had statistical significance. The levels of IL-6:were no difference between two groups ( 8.76±3.27 u g/L VS 7.30±2.30u g/L P>0.05) . (5) The levels of CTN-I in plasma from SAPN UAP patients were positively associated with that of CRPi and that of IL-6i respectively ( r=0.4416 P<0.05; r=0.5859 P<0.05 ) , the CRPi levels were also positively associated with the IL-6i levels in SAP, UAP patients (r=0.4246 P<0.05) .(6)The levels of CRPi and IL-6j in plasma from those CAD patients with DM were higher than that of CAD patients without DM ( 25.43 ± 12.86mg/L VS 13.18 ± 7.37 mg/L P<0.05: 17.01±5.98u g/L VS 7.51 ±3.64n g/L P<0.05) . The levels of CRPi and IL-6i in plasma from those CAD patients with EH were higher than that of CAD patients without EH (23.48±11.57mg/L VS 15.09±6.39mg/L P<0.05; 15.96± 9.03u g/L VS 8.05 ± 2.58 u g/LP<0.05)0[ Conclusions](1) Compared to non-CAD controls, the levels of CRP and IL-6 in plasma from patients with CAD were higher , this results indicate the potential roles played by CRP and IL-6 in pathogenesis and progress of CAD.(2) The levels of CRP and IL-6 have... |
PDF Full Text Request